News – Page 1147 – Endpoints News

Novartis chief Jimenez touts two top PhIII drug prospects

9 years ago

Merrimack recruits Sanofi vet Richard Peters for the top job; ObsEva and Braeburn detail their IPO shots

9 years ago

Eli Lilly nabs CoLucid and a PhIII migraine drug in $960M buyout

9 years ago

Ovid and Takeda create a one-team strategy to steer a neuro drug to the world

9 years ago

SEC hands Allergan a $15M speeding ticket for blowing off disclosure rules in a tough 2014 fight against Valeant

9 years ago

Neurocrine execs shrug off a PhII setback for Tourette syndrome

9 years ago

Upstart maps plans to build fibrosis pipeline; FDA extends review period for Lilly’s baricitinib

9 years ago

Lagging further behind, AstraZeneca adds fresh details to its checkpoint comeback strategy

9 years ago

Biogen to pay $1.25B to de-risk a Tecfidera patent battle, and Forward Pharma’s shares rocket up

9 years ago

Alcobra blasted by a PhIII flop for ADHD drug as its options dwindle

9 years ago

Allergan aces another promising PhIII on uterine fibroid therapy, with plans to hustle the bundle to the FDA

9 years ago

In his latest broadside on drug prices, Trump plays the Medicare negotiations card

9 years ago

After talking to Trump about top FDA job, Balaji Srinivasan erased his barbed criticism of the drug agency

9 years ago

OncoImmune raises $15M for PhII GvHD study; FDA wraps biosimilar naming guidance

9 years ago

Armed with $137M fund, Signet launches hunt for a dozen new biotech plays

9 years ago

Trump nukes biopharma, and the fallout is radioactive

9 years ago

Is Spinraza worth $750K? Biogen says yes, spelling out reduced death risk

9 years ago

Investigators signal thumbs-up for antibiotic, prep an FDA pitch for OK

9 years ago

Failed Nivalis pares down to a skeleton crew as it launches a salvage operation

9 years ago

Pfizer wants you. And you. And you. And you.

9 years ago

Biogen spinoff begins trading today; New oncology chief at AstraZeneca

9 years ago

As Trump fingers pharma on drug prices, execs step up with the latest vows of self discipline

9 years ago

Vision or voodoo? Biotech IPO master Vivek Ramaswamy is still setting up new biotechs and hatching more deals

9 years ago

FDA rejects Tesaro’s IV version of rolapitant, citing manufacturing issues

9 years ago

First page Previous page 1144 1145 114611471148 1149 1150 Next page Last page